Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol 26-week extension in COPD
NCT00677807Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Novartis. Primary endpoints: Clinically Notable Pulse Rate at 52 weeks, Clinically Notable Systolic Blood Pressure at 52 weeks and 4 more. Started May 2008; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00677807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00677807.